|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 27430 |
FusionGeneSummary for PLA2G16_PLA2G16 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PLA2G16_PLA2G16 | Fusion gene ID: 27430 | Hgene | Tgene | Gene symbol | PLA2G16 | PLA2G16 | Gene ID | 11145 | 11145 |
| Gene name | phospholipase A2 group XVI | phospholipase A2 group XVI | |
| Synonyms | AdPLA|H-REV107|H-REV107-1|HRASLS3|HREV107|HREV107-1|HREV107-3|HRSL3 | AdPLA|H-REV107|H-REV107-1|HRASLS3|HREV107|HREV107-1|HREV107-3|HRSL3 | |
| Cytomap | 11q12.3-q13.1 | 11q12.3-q13.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | HRAS-like suppressor 3Ca-independent phospholipase A1/2H-rev 107 protein homologHRAS-like suppressor 1adipose-specific PLA2adipose-specific phospholipase A2group XVI phospholipase A1/A2group XVI phospholipase A2renal carcinoma antigen NY-REN-65 | HRAS-like suppressor 3Ca-independent phospholipase A1/2H-rev 107 protein homologHRAS-like suppressor 1adipose-specific PLA2adipose-specific phospholipase A2group XVI phospholipase A1/A2group XVI phospholipase A2renal carcinoma antigen NY-REN-65 | |
| Modification date | 20180519 | 20180519 | |
| UniProtAcc | P53816 | P53816 | |
| Ensembl transtripts involved in fusion gene | ENST00000323646, ENST00000415826, ENST00000394613, | ENST00000323646, ENST00000415826, ENST00000394613, | |
| Fusion gene scores | * DoF score | 3 X 3 X 3=27 | 3 X 3 X 3=27 |
| # samples | 3 | 3 | |
| ** MAII score | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: PLA2G16 [Title/Abstract] AND PLA2G16 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PLA2G16 | GO:0006644 | phospholipid metabolic process | 20100577 |
| Tgene | PLA2G16 | GO:0006644 | phospholipid metabolic process | 20100577 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BE166188 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3UTR | ENST00000323646 | ENST00000323646 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| intron-3UTR | ENST00000323646 | ENST00000415826 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| intron-intron | ENST00000323646 | ENST00000394613 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| intron-3UTR | ENST00000415826 | ENST00000323646 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| intron-3UTR | ENST00000415826 | ENST00000415826 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| intron-intron | ENST00000415826 | ENST00000394613 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| intron-3UTR | ENST00000394613 | ENST00000323646 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| intron-3UTR | ENST00000394613 | ENST00000415826 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
| intron-intron | ENST00000394613 | ENST00000394613 | PLA2G16 | chr11 | 63342057 | - | PLA2G16 | chr11 | 63342180 | + |
Top |
FusionProtFeatures for PLA2G16_PLA2G16 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PLA2G16 | PLA2G16 |
| Lipid-modifying enzyme that acts as major regulator ofadipocyte lipolysis by catalyzing the release of fatty acids fromphospholipids in adipose tissue (PubMed:19615464, PubMed:19047760,PubMed:20837014, PubMed:22605381, PubMed:22923616). Showsphospholipase A1 and A2 activity, catalyzing the calcium-independent hydrolysis of acyl groups in variousphosphatidylcholines (PC) and phosphatidylethanolamine (PE)(PubMed:19615464, PubMed:19047760, PubMed:20837014,PubMed:22605381, PubMed:22923616). For most substrates,phospholipase A1 activity is much higher than phospholipase A2activity (PubMed:19047760). Phospholipase activity causesdecreased intracellular levels of ether-type lipids, affectingperoxisome metabolism (By similarity). May also haveacyltransferase activity: catalyzes both N-acylation ofphosphatidylethanolamine to form N-acyl-phosphatidylethanolamineand O-acylation of lyso-phosphatidylcholines to formphosphatidylcholines (PubMed:22605381, PubMed:25383759). Therelevance of acyltransferase activity in vivo is however unclearand would require additional evidences (PubMed:22605381,PubMed:25383759). Also has weak lysophospholipase activity (Bysimilarity). {ECO:0000250|UniProtKB:Q8R3U1,ECO:0000269|PubMed:17374643, ECO:0000269|PubMed:19047760,ECO:0000269|PubMed:19615464, ECO:0000269|PubMed:20837014,ECO:0000269|PubMed:22605381, ECO:0000269|PubMed:22923616,ECO:0000269|PubMed:25383759}. (Microbial infection) Acts as a host factor forpicornaviruses: required during early infection to promote viralgenome release into the cytoplasm (PubMed:28077878). May act as acellular sensor of membrane damage at sites of virus entry, whichrelocalizes to sites of membrane rupture upon virus unfection(PubMed:28077878). Facilitates safe passage of the RNA away fromLGALS8, enabling viral genome translation by host ribosome(PubMed:28077878). May also be involved in initiating poreformation, increasing pore size or in maintaining pores for genomedelivery (PubMed:28077878). The lipid-modifying enzyme activity isrequired for this process (PubMed:28077878).{ECO:0000269|PubMed:28077878}. | Lipid-modifying enzyme that acts as major regulator ofadipocyte lipolysis by catalyzing the release of fatty acids fromphospholipids in adipose tissue (PubMed:19615464, PubMed:19047760,PubMed:20837014, PubMed:22605381, PubMed:22923616). Showsphospholipase A1 and A2 activity, catalyzing the calcium-independent hydrolysis of acyl groups in variousphosphatidylcholines (PC) and phosphatidylethanolamine (PE)(PubMed:19615464, PubMed:19047760, PubMed:20837014,PubMed:22605381, PubMed:22923616). For most substrates,phospholipase A1 activity is much higher than phospholipase A2activity (PubMed:19047760). Phospholipase activity causesdecreased intracellular levels of ether-type lipids, affectingperoxisome metabolism (By similarity). May also haveacyltransferase activity: catalyzes both N-acylation ofphosphatidylethanolamine to form N-acyl-phosphatidylethanolamineand O-acylation of lyso-phosphatidylcholines to formphosphatidylcholines (PubMed:22605381, PubMed:25383759). Therelevance of acyltransferase activity in vivo is however unclearand would require additional evidences (PubMed:22605381,PubMed:25383759). Also has weak lysophospholipase activity (Bysimilarity). {ECO:0000250|UniProtKB:Q8R3U1,ECO:0000269|PubMed:17374643, ECO:0000269|PubMed:19047760,ECO:0000269|PubMed:19615464, ECO:0000269|PubMed:20837014,ECO:0000269|PubMed:22605381, ECO:0000269|PubMed:22923616,ECO:0000269|PubMed:25383759}. (Microbial infection) Acts as a host factor forpicornaviruses: required during early infection to promote viralgenome release into the cytoplasm (PubMed:28077878). May act as acellular sensor of membrane damage at sites of virus entry, whichrelocalizes to sites of membrane rupture upon virus unfection(PubMed:28077878). Facilitates safe passage of the RNA away fromLGALS8, enabling viral genome translation by host ribosome(PubMed:28077878). May also be involved in initiating poreformation, increasing pore size or in maintaining pores for genomedelivery (PubMed:28077878). The lipid-modifying enzyme activity isrequired for this process (PubMed:28077878).{ECO:0000269|PubMed:28077878}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for PLA2G16_PLA2G16 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for PLA2G16_PLA2G16 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PLA2G16_PLA2G16 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for PLA2G16_PLA2G16 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|